Article
Novartis Ophthalmics and Valley Forge Pharmaceuticals Inc. have entered into a licensing agreement for a novel eye medication for myopia, which in phase II clinical trials reduced progression of the disease by 50% in the first 12 months of therapy.
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.